Intellia Therapeutics
Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
NTLA Key Statistics
Stock Snapshot
As of today, Intellia Therapeutics(NTLA) shares are valued at $15.19. The company's market cap stands at 1.83B, with a P/E ratio of -4.03.
During the trading session on 2026-03-02, Intellia Therapeutics(NTLA) shares reached a daily high of $15.89 and a low of $12.75. At a current price of $15.19, the stock is +19.1% higher than the low and still -4.4% under the high.
Trading volume for Intellia Therapeutics(NTLA) stock has reached 14.44M, versus its average volume of 3.95M.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
Over the past 52 weeks, Intellia Therapeutics(NTLA) stock has traded between a high of $28.25 and a low of $5.90.
NTLA News
Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $27 from $26 and keeps a Buy rating on the shares after the FDA lifted the clinical ho...
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement. On March 2, 2026, Intellia Therapeutics, Inc. amended its at-the-market equity offering agreeme...
FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intel...
Analyst ratings
50%
of 24 ratingsMore NTLA News
Intellia Therapeutics Inc ((NTLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-...
Image source: The Motley Fool. Thursday, Feb. 26, 2026 at 8 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — John Leonard Chief Financial Offi...
Intellia Therapeutics (NTLA) is in focus after a busy stretch, with Q4 2025 results exceeding earnings and revenue expectations, encouraging hereditary angioede...
Reports Q4 revenue $23.017M, consensus $12.17M. “2025 was a time of accomplishment and resiliency for Intellia as we presented encouraging longer term Phase 1/2...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.